Colgate-Palmolive Company (NYSE:CL) today reported results for fourth quarter and full year 2025.
Fourth-quarter net sales increased 5.8%; Organic sales increased 2.2%, including a 0.9% negative impact from lower private label pet volume
GAAP EPS declined 106% to $(0.05), driven by goodwill and intangible assets impairment charges related to the skin health business
During the fourth quarter, the Company took a non-cash, after-tax charge of $794 million to adjust the carrying values of goodwill and intangible assets related to the skin health business.
Given lower than expected category growth rates and weaker than expected performance, particularly in China, the Company has lowered its outlook for the skin health business, primarily Filorga.
The Company is taking the appropriate actions to improve performance and continues to believe in the growth prospects of the business.
For the full-year the Company expects net sales to be up 2% to 6%, including a low-single-digit positive impact from foreign exchange.
CEO Noel Wallace, commented on the Base Business fourth quarter and full year results, “We are pleased to have exited 2025 with accelerated growth momentum on both the top and bottom lines, even in the face of sluggish category growth in many markets. Net sales and organic sales grew in every category during the quarter, led by strength in oral care and pet nutrition, excluding private label.”
CL shares vaulted $4.13, or 4.9%, to $89.23.
